A phase 2 study of three low-dose intensity subcutaneous Bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Larocca A et al. Leukemia. 2016 Feb 22. doi: 10.1038/leu.2016.36. [Epub ahead of print].
A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone.
Zwickl H et al. Leuk Lymphoma. 2016 Feb 22:1-6. [Epub ahead of print].
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom MyelomaForum Myeloma X (Intensive) Trial.
Parrish C et al. Biol Blood Marrow Transplant. 2016 Jan 28. pii: S1083-8791(16)00056-2. doi: 10.1016/j.bbmt.2016.01.016. [Epub ahead of print]
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE et al. Br J Clin Pharmacol. 2016 Feb 15. doi: 10.1111/bcp.12906. [Epub ahead of print].
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractorymultiple myeloma: MM-024 Extended Access Program.
Du X et al. BMC Cancer. 2016 Jan 28;16(1):46. doi: 10.1186/s12885-016-2069-8.